Trial Information

Summary: Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine

Phase 3B, Multicenter, Multinational, Double-Blind, Placebo Controlled, 2-Arm Trial to Evaluate the Effect of the 24-Hour Transdermal Delivery of Rotigotine on the Control of Early Morning Motor Function, Sleep Quality, Nocturnal Symptoms, and Non-Motor Symptoms in Subjects With Idiopathic Parkinson's Disease

The objective of this trial is to assess the effects of rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsonsīs disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinsonīs disease will be evaluated.

Inclusion Criteria:

• Early and advanced Idiopathic Parkinson Disease with early morning motor impairment

Exclusion Criteria:

• Therapy with a dopamine agonist within the first 28 days after enrollment

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: March 17, 2008 at 3:02:07 PM